Pfizer's CEO says he's got a plan to deal with Trump's tariffs — move overseas drug manufacturing to the US
1. Pfizer may move manufacturing back to the US due to tariffs. 2. CEO Albert Bourla acknowledges Trump’s tariffs will impact operations. 3. Pfizer has 13 operational manufacturing sites in the US. 4. The pharmaceutical industry is closely monitoring tariff implications. 5. Bourla did not see Trump's victory as a surprise.